Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox Study stopped enrolling patients in all study arms ...
LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback